Press Releases

Date	Title	PDF Version
Jan 16, 2014	Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Results on Thursday, January 30, 2014
Jan 13, 2014	Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics™ for Rare Diseases
Jan 08, 2014	Alexion to Present at the JP Morgan 32nd Annual Healthcare Conference
Dec 13, 2013	Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion
Dec 08, 2013	New Data Presented at ASH Annual Meeting Enhance Understanding of PNH and aHUS to Provide Optimal Care for Patients with These Life-threatening Disorders
Nov 09, 2013	Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Nov 07, 2013	Researchers to Present Clinical Trial Data With Soliris® (eculizumab) Treatment in Both Approved Indications — PNH and aHUS — at ASH Annual Meeting
Nov 07, 2013	Alexion to Present at Credit Suisse 2013 Healthcare Conference
Oct 24, 2013	Alexion Reports Third Quarter 2013 Results
Oct 24, 2013	FDA Grants Breakthrough Therapy Designation to cPMP Replacement Therapy for Patients with Molybdenum Cofactor Deficiency (MoCD) Type A

Search